The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Main Article Content

Amy S Paller
Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University

Jonathan I Silverberg
The George Washington School of Medicine and Health Sciences

Chih-ho Hong
Department of Dermatology and Skin Science, University of British Columbia and Probity Medical Research

Michael Cork
The University of Sheffield and Sheffield Teaching Hospitals

Luis Puig
Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona

Petra Arlert
Leo Pharma Inc.

Azra Kurbasic
Leo Pharma Inc.

Lise Soldbro
Leo Pharma Inc.

Eric L Simpson
Oregon Health & Science University

Keywords

tralokinumab, quality of life, adolescents, atopic dermatitis, phase 3, clinical trial

References

1. Bieber T. Allergy. 2020;75:54–62

2. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480–89

3. Popovic B, et al. J Mol Biol. 2017;429:208–19

4. Ng M, et al. Australas J Dermatol. 2018;59:e114-e17

5. Ghio D, et al. Br J Health Psychol. 2021;26:214-31

6. Manjunath J, et al. J Eur Acad Dermatol Venereol. 2022;36:e346–e48

7. Wollenberg A, et al. Presented at European Society for Pediatric Dermatology 21st Annual Meeting 2022

8. Paller A, et al. Presented at 2021 Fall Clinical Dermatology Conference 40th Annual Meeting.

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.77

Article Details

How to Cite
[1]
Paller, A.S., Silverberg, J.I., Hong, C.- ho, Cork, M., Puig, L., Arlert, P., Kurbasic, A., Soldbro, L. and Simpson, E.L. 2022. The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s77. DOI:https://doi.org/10.25251/skin.6.supp.77.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>